Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Pemro
Beacon Pharmaceuticals PLC
Generic: Pembrolizumab
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Pemro. Please consult your doctor.
CONSULT YOUR DOCTOR
Pemro may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
CONSULT YOUR DOCTOR
Pemro is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
CONSULT YOUR DOCTOR
It is not known whether Pemro alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
CAUTION
Pemro should be used with caution in patients with kidney disease. Dose adjustment of Pemro may be needed. Please consult your doctor.
CAUTION
Pemro should be used with caution in patients with liver disease. Dose adjustment of Pemro may be needed. Please consult your doctor.
Medicine Overview of Pemro 100mg/4ml Injection
Introduction
Pemro is used in the treatment of melanoma, non-small cell lung cancer, head and neck cancer, and cervical cancer. Pemro is given as an infusion into the vein by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for...
... Show moreUses of Pemro
- Melanoma
- Non-small cell lung cancer
- Head and neck cancer
- Cervical cancer
Side effects of Pemro
Common
- Rash
- Fatigue
- Fever
- Musculoskeletal (bone, muscle or joint) pain
- Stomach pain
- Nausea
- Itching
- Constipation
- Indigestion
- Diarrhea
- Decreased appetite
- Cough
How to use Pemro
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Pemro works
Pemro is an anti-cancer medication. It works in certain cancer by working with immune system thereby activating T-cell mediated immune responses against tumor cells.
Quick Tips
- Pemro helps your immune system fight cancer such as that of head, neck, lung, and skin.
- It is usually given through an infusion into your vein (IV) for about 30 minutes, every 3 weeks, by your doctor.
- It may make you feel tired or weak. Do not drive or use machines unless you are sure you are feeling well.
- Take adequate birth control measures while you are being treated with this medicine and for at least 4 months after your last dose, as it can cause harm to an unborn baby.
- Do not stop treatment without talking to your doctor first.
Brief Description
Indication
Metastatic melanoma, Unresectable melanoma, Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma, Gastro-oesophageal junction adenocarcinoma, Locally advanced urothelial carcinoma, Metastatic gastric cancer, Metastatic microsatellite instability-high cancer, Metastatic squamous cell carcinoma of the head and neck, Metastatic urothelial carcinoma, Recurrent locally advanced gastric cancer, Recurrent squamous cell carcinoma of the head and neck, Refractory classical Hodgkin lymphoma, Relapsed classical Hodgkin lymphoma, Unresectable microsatellite instability-high cancer.
Administration
IV Preparation Reconstitute vial by adding 2.3 mL of Sterile Water for Injection (resulting concentration 25 mg/mL) Slowly swirl vial; allow up to 5 minutes for bubbles to clear Do NOT shake vial Visually inspect reconstituted solution for particulate matter and discoloration prior to administration Reconstituted solution should appeared clear to slightly opalescent, colorless to slightly yellow solution; discard if extraneous particulate matter other than translucent to white proteinaceous particles is observed IV infusion preparation Withdraw required volume from vial(s) and transfer into IV bag containing 0.9% NaCl or D5W; mix diluted solution by gentle inversion Final concentration of diluted...
... Show moreAdult Dose
Intravenous Metastatic melanoma, Unresectable melanoma Adult: 2 mg/kg or 200 mg once every 3 weeks via infusion over 30 minutes, until disease progression or unacceptable toxicity. Dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur. Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma Adult: In patients who have been treated with chemotherapy: 2 mg/kg once every 3 weeks via infusion over 30 minutes, until disease progression or unacceptable toxicity. Dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur. Metastatic non-small cell...
... Show moreMode of Action
Pembrolizumab is a humanised immunoglobulin G4 monoclonal antibody which binds to the cell surface receptor programmed death-1 (PD-1), a negative immunoregulatory protein, and prevents it from interacting with ligands PD-L1 and PD-L2. Blockade of the PD-1 pathway results in the reactivation of T-lymphocytes and induction of immune response to tumour cells.
Precaution
Patient with autoimmune disorders. Patients who received allogeneic haematopoietic stem cell transplant (HSCT) or solid organ transplant. Not indicated for multiple myeloma. Pregnancy and lactation.
Lactation
Unknown if distributed in human breast milk
No studies conducted to assess impact of pembrolizumab on milk production or its presence in breast milk
Instruct women to discontinue nursing during treatment and for 4 months after final dose
Side Effect
Significant: Colitis, hepatitis, nephritis, severe endocrinopathies (e.g. diabetic ketoacidosis, diabetes mellitus, hypo- or hyperthyroidism, hypophysitis, severe infusion-related reactions (e.g. hypersensitivity, anaphylaxis); hepatic veno-occlusive disease in patients with classical Hodgkin lymphoma undergoing allogeneic HSCT. Blood and lymphatic system disorders: Anaemia. Gastrointestinal disorders: Abdominal pain, constipation, diarrhoea, dry mouth, nausea, vomiting. General disorders and administration site conditions: Fatigue, asthenia, oedema, chills, pyrexia, influenza-like illness. Investigations: Increased AST/ALT, alkaline phosphatase, and blood creatinine. Metabolism and nutrition disorders: Decreased appetite. Musculoskeletal and connective tissue disorders: Musculoskeletal pain, arthralgia, arthritis, myositis, pain in extremity. Nervous system disorders: Dizziness, dysgeusia, headache. Respiratory, thoracic and mediastinal disorders:...
... Show moreInteraction
Use of systemic corticosteroids or immunosuppressants before starting therapy may cause interference with the pharmacodynamic activity and efficacy of pembrolizumab.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register